# Research Watch: Headlines Worth Watching — September 8, 2026

**URL:** <https://community.i-om.ai/t/research-watch-headlines-worth-watching-september-8-2026/248>\
**Category:** Headlines Worth Watching\
**Created:** [September 8, 2026, 11:07am UTC](https://community.i-om.ai/t/research-watch-headlines-worth-watching-september-8-2026/248 "2026-09-08T11:07:50Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![I-OM.ai](https://community.i-om.ai/letter_avatar_proxy/v4/letter/i/c68b51/32.png) [@I-OM.ai](https://community.i-om.ai/u/I-OM.ai)\
**Post date:** [September 8, 2026, 11:07am UTC](https://community.i-om.ai/t/research-watch-headlines-worth-watching-september-8-2026/248/1 "2026-09-08T11:07:51Z")

</div>

## Longevity & Aging: Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.

**Why it matters:** Relevant to I-OM domains of Longevity & Healthy Aging, specifically intersecting with root drivers of metabolic dysfunction and major biological processes of cellular senescence, chronic inflammation, and impaired repair. The study provides a novel methodological framework for assessing these processes via proteomic biomarkers in human trials. Supports the conceptual feasibility of integrating proteomic aging endpoints into disease-specific clinical trials to simultaneously assess geroprotective potential.

**What the evidence actually shows:** Six proteomic aging clocks (ProtAge, OrganAgemortality, OrganAgechrono, PAC, ipfP3GPT, PAOPAC) consistently predicted lower biological age in rentosertib-treated arms versus controls in a 12-week phase 2a IPF trial.

**What we don’t know yet:** Secondary analysis of a previously published phase 2a trial; sample size and statistical power for aging endpoints are likely limited by the original trial design.

**Research Watch verdict:** Early

* * *

## Emerging Cancer Technology: A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

**Why it matters:** Minimal to none. This is a neurointerventional surgical device study unrelated to I-OM’s focus on nutritional, metabolic, environmental, or systems-based root drivers of disease. The procedural use of microvascular occlusion does not relate to I-OM’s concept of pathological microvascular dysfunction. Results support continued clinical investigation of NeoCast for pre-surgical embolization but are insufficient to change current neurointerventional practice due to the small feasibility-stage sample size.

**What the evidence actually shows:** NeoCast achieved complete occlusion in all targeted vessels across all 5 enrolled subjects.

**What we don’t know yet:** Extremely small sample size (n=5), limiting generalizability and statistical power.

**Research Watch verdict:** Promising

* * *

**Want the important health research without the noise? Follow I-OM Research Watch for daily evidence updates.**
